| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968976 | TAKEDA PHARMS USA | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
Oct, 2018
(5 years ago) | |
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(4 months from now) | |
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(4 months from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(6 years from now) | |
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(6 years from now) | |
Fosrenol is owned by Takeda Pharms Usa.
Fosrenol contains Lanthanum Carbonate.
Fosrenol has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Fosrenol are:
- US5968976
Fosrenol was authorised for market use on 23 November, 2005.
Fosrenol is available in powder;oral, tablet, chewable;oral dosage forms.
Fosrenol can be used as reduction of serum phosphate, reduction of serum phosphate in patients with end stage renal disease.
The generics of Fosrenol are possible to be released after 01 December, 2030.
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 23 November, 2005
Treatment: Reduction of serum phosphate; Reduction of serum phosphate in patients with end stage renal disease
Dosage: POWDER;ORAL; TABLET, CHEWABLE;ORAL
FOSRENOL family patents
